43 results
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
2 Nov 23
Ocuphire Corporate Presentation November 2023
8:44am
; DME = Diabetic Macular Edema ; BRVO = Branch Retinal Vein Occlusion National Center for Chronic Disease Prevention & Health Promotion. Health & economic … costs of chronic diseases. Atlanta (GA): Centers for Disease Control & Prevention, US Department of Health and Human Services; 2018 Four-Year Visual
424B5
OCUP
Ocuphire Pharma Inc
14 Aug 23
Prospectus supplement for primary offering
8:00am
for presbyopia and DLD as well as a supportive long-term safety trial for chronic use of Nyxol in refractive indications.
Corporate Information
Our … ) are approved globally, but these chronic therapies require frequent biweekly or monthly office visits and are prone to side effects such as hemorrhage
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
1 Aug 23
Restore Vision & Clarity Ocuphire Corporate Presentation August 2023
11:21am
) AMD = Age-Related Macular Degeneration; DME = Diabetic Macular Edema ; BRVO = Branch Retinal Vein Occlusion National Center for Chronic Disease … Prevention & Health Promotion. Health & economic costs of chronic diseases. Atlanta (GA): Centers for Disease Control & Prevention, US Department of Health
8-K
EX-99.1
u7sycn1yupfawyno4
30 Mar 23
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update
9:05am
8-K
EX-99.1
mn0fkb5d
14 Oct 22
Regulation FD Disclosure
11:32am
8-K
EX-99.1
p1mk vpjmd605t
12 Aug 22
Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update
7:51am
8-K
EX-99.2
oryo0
12 Aug 22
Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update
7:51am
8-K
EX-99.2
69jh06r5881kom
19 May 22
Regulation FD Disclosure
7:43am
8-K
EX-99.1
ipnzfs87umghm5vt4br
19 May 22
Regulation FD Disclosure
7:43am
8-K
EX-99.1
lhd i83gf
29 Mar 22
Regulation FD Disclosure
8:25am
8-K
EX-99.1
bfggh9j8d2 odee42i7e
24 Mar 22
Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended 2021 and Provides Corporate Update
8:17am
8-K
EX-99.2
vw7c iixuissh1
5 Jan 22
Completed Enrollment of Nyxol® LYNX-1 Phase 3 NVD Trial
7:05am
8-K
EX-99.2
01hd80tt1kn c1lu
15 Nov 21
Ocuphire Announces Financial Results for the Third Quarter 2021 and Provides Corporate Update
12:00am